Abstract
Biosensors are essential tools designed to monitor physiologically significant data for diverse applications, including environmental pollution detection, food safety, medication research, and disease diagnosis. The integration of microfluidics, nanotechnology, and advanced electronics has significantly advanced the development of wearable and implantable biosensors for managing chronic diseases such as cancer, diabetes, and glaucoma. Among these, glaucoma remains a leading cause of visual impairment, predominantly driven by elevated intraocular pressure (IOP), with limited treatment effectiveness due to challenges like suboptimal drug bioavailability and therapeutic inefficiency. Despite advances, unmet needs in early diagnosis and sustained management persist, demanding innovative solutions.Recent advancements in nanotechnology offer transformative potential, addressing these challenges by enhancing both the detection and treatment of ocular diseases. This review explores cutting-edge developments in nano-drug delivery systems and continuous IOP monitoring technologies. Particular emphasis is placed on nanoparticle and nanofiber-based biosensors and contact lenses, which represent a promising leap forward in improving therapeutic precision and patient outcomes in glaucoma care. The manuscript uniquely contributes by synthesizing these advancements and highlighting their potential to bridge existing gaps in glaucoma management.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call